Cerus Corporation (CERS)
-NasdaqGM | Prev Close: | 6.79 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 7.40 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.68 - 6.95 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 543,947 |
|---|
| Market Cap: | 473.51M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Cerus submits the first of three modules in the premarket approval application process for INTERCEPT plateletsBriefing.com(Tue, Oct 1)
- Cerus Submits the First of Three Modules in the Premarket Approval (PMA) Application Process for INTERCEPT PlateletsBusiness Wire(Tue, Oct 1)
- Cerus to Present at the Baird's 2013 Health Care Conference on September 10, 2013Business Wire(Wed, Sep 4)
- Still Time To Catch Big Growth In Biotech: George Zavoicoat Seeking Alpha(Thu, Aug 15)
- CERUS CORP FinancialsEDGAR Online Financials(Fri, Aug 9)
- Cerus to Present at the Wedbush 2013 Life Sciences Management Access Conference on August 14, 2013Business Wire(Wed, Aug 7)
- CERUS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, Aug 2)
- Cerus Corp's Intercept Blood System Progress Reportat Seeking Alpha(Fri, Aug 2)
- Cerus Misses on Both Revenue and Earningsat Motley Fool(Wed, Jul 31)
- Following the Blood Trail to Three Worthy Healthcare Investmentsat Motley Fool(Wed, Jul 31)
- Cerus Management Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Jul 30)
- Cerus Corporation Reports Second Quarter 2013 ResultsBusiness Wire(Tue, Jul 30)
- CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, Jul 30)
- Q2 2013 Cerus Corporation Earnings Release - After Market CloseCCBN(Tue, Jul 30)
- 5 Stocks Under $10 Set to Soarat TheStreet(Thu, Jul 11)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 12.25 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.45 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
View More